Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

NCT05317078 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05317078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05317078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2023
Completion date
April 1, 2024
Enrollment
3 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

claudin 6-positive advanced/metastatic malignant solid tumors, epithelial ovarian cancer, non-squamous non-small cell lung cancer